Novo Holdings has for nearly $462m (鈧�433.67m) to bolster its antimicrobial resistance (AMR) expertise.
In June 2023, Novo Holdings announced the signing of a definitive agreement to acquire Paratek.
Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.
A lead product of the company, Nuzyra (omadacycline), is currently available in the US as a once-a-day oral and intravenous antibiotic.
The treatment is indicated for use in adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Paratek is currently carrying out a Phase IIb clinical trial of Nuzyra for nontuberculous mycobacterial (NTM) pulmonary disease.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe company also has a partnership agreement in place with for omadacycline鈥檚 development and marketing in greater China and retains all worldwide rights for ex-greater China markets.
Novo Holdings partner Aleks Engel said: 鈥淲e are committed to maintaining Paratek鈥檚 leadership in reaching patients and delivering innovative products across the globe.
鈥淲e look forward to supporting the continued growth of Nuzyra, and the expansion of Paratek鈥檚 product portfolio, including the acquisition or licensing of other therapeutics in antibiotics and beyond.鈥�
Novo Holdings is a holding and investment company that manages Novo Nordisk Foundation and healthcare investment firm Gurnet Point鈥檚 assets and wealth.
